Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIA632 dose-ranging study in adults with non-segmental vitiligo
2025-522301-37-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in Vitiligo comparing GIA632 with Placebo to GIA632 (2 arms). Primary endpoint: Percentage change from baseline to Week 24 in F-VASI score. Planned start Jun 2026; status: authorised.
02
Drugs
GIA632
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2025-522301-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522301-37-00.